A股異動 | 愛爾眼科(300015.SZ)漲超8% 一季度淨利同比增長509.88%
格隆匯4月23日丨愛爾眼科(300015.SZ)高開高走一度大漲9.79%至69.88元,現漲幅收窄至8.08%,報68.79元,暫成交23億元,最新總市值2835億元。愛爾眼科昨日晚間公吿,公司2021年度一季度實現營業收入35.11億元,同比增長113.90%;淨利潤4.84億元,同比增長509.88%;歸屬於上市公司股東的扣除非經常性損益的淨利潤5.09億元,同比增長1870.84%。愛爾眼科表示,一方面,公司品牌影響力持續增強,各項業務規模不斷提升,市場佔有率持續提高;居民眼健康意識逐步加強,醫療消費穩步升級;加之國家近視防控戰略、防盲治盲等政策的推進實施,共同促進了業績的快速增長;另一方面,由於去年同期經營業績受疫情影響,可比期基數較低。截止到今年3月31日,公司境內醫院149家,門診部93家。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.